HeXun Biosciences Co Ltd AI Stock Analysis
HeXun Biosciences Co Ltd (6986) AI Stock Analysis
HeXun Biosciences Co Ltd
(TPEx:6986)
HeXun Biosciences earns an above-average score driven primarily by its strong financial foundation — exceptional margins, solid free cash flow and an essentially debt-free balance sheet that is rare for a small-cap biotech. A reasonable P/E of 15.9 adds further support. The score is held back by a pronounced technical downtrend, with the stock trading below all key moving averages and MACD in negative territory, alongside fundamental signs of a plateau: stalled revenue growth, declining net income and margin compression that pulled return on equity down to 15%. Deeply oversold readings suggest scope for a near-term rebound, but a durable re-rating likely requires evidence that growth and margins can reaccelerate.
HeXun Biosciences Co Ltd (6986) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.94B
- Dividend Yield
- 0.52%
- Average Volume (3M)
- 67.30K
- Price to Earnings (P/E)
- 14.1
- Beta (1Y)
- 0.25
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- TW
- Employees
- 53
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
HeXun Biosciences Co Ltd Business Overview & Revenue Model
Company Description
HeXun Biosciences Co., Ltd., a Taiwanese enterprise, focuses on the research, development, and application of stem cell technologies and treatments. The company also offers a comprehensive suite of related services, including contract development and...
HeXun Biosciences Co Ltd Financial Statement Overview
Summary
A financially robust small-cap biotech: gross margin near 84%, net margin close to 38%, operating cash flow of roughly NT$164M and free cash flow of about NT$135M, all supported by a near debt-free balance sheet (debt-to-equity of 0.05, equity funding ~89% of assets). Earnings quality is high, with operating cash flow at ~1.5x net income. The offsetting concern is momentum: after years of rapid scaling, revenue growth has flattened to low single digits, net income fell from about NT$147M to NT$112M, margins compressed, and return on equity slipped from 24% to 15%.
Income Statement
71PositiveBalance Sheet
88Very PositiveCash Flow
81Very Positive| Breakdown | TTM | Dec 2025 | Dec 2025 | Dec 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 308.21M | 130.57M | 293.23M | 286.42M | 49.47M | 0 |
| Gross Profit | 263.83M | 113.73M | 245.15M | 260.67M | 44.61M | 0 |
| EBITDA | 164.03M | 55.64M | 146.95M | 187.36M | 11.17M | -29.51M |
| Net Income | 116.33M | 33.49M | 111.91M | 147.22M | -5.19M | -42.99M |
Balance Sheet | ||||||
| Total Assets | 1.18B | 571.43M | 837.07M | 706.92M | 404.15M | 294.62M |
| Cash, Cash Equivalents and Short-Term Investments | 828.93M | 329.67M | 509.63M | 372.99M | 191.74M | 85.03M |
| Total Debt | 34.66M | 70.06M | 36.58M | 35.02M | 69.42M | 74.10M |
| Total Liabilities | 109.95M | 98.07M | 95.47M | 86.34M | 89.28M | 79.86M |
| Stockholders Equity | 1.07B | 473.36M | 741.60M | 620.58M | 314.87M | 214.75M |
Cash Flow | ||||||
| Free Cash Flow | 133.02M | 20.28M | 135.04M | 83.63M | 10.00M | -35.50M |
| Operating Cash Flow | 163.75M | 43.09M | 163.89M | 120.92M | 11.23M | -35.50M |
| Investing Cash Flow | -209.38M | -25.28M | -158.38M | -137.29M | -79.05M | -26.95M |
| Financing Cash Flow | 264.50M | 120.12M | 1.69M | -40.30M | 102.54M | 75.79M |
HeXun Biosciences Co Ltd Peers Comparison
Overall Rating
- TW:698667Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:6986 | 67Neutral | TWD 1.94B | 14.13 | ― | 0.52% | ― | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6986 | HeXun Biosciences Co Ltd | 37.50 | -23.42 | -38.45% | |
| TW:6704 | Gwo Xi Stem Cell Applied Technology Co., Ltd. | 20.20 | -5.90 | -22.61% | |
| TW:6808 | 3D Global Biotech Inc. | 26.10 | -19.30 | -42.51% | |
| TW:6932 | Merdury Biopharmaceutical Corporation | 5.23 | -5.02 | -48.98% | |
| TW:6973 | U-Neuron Biomedical Inc | 54.89 | 14.16 | 34.75% | |
| TW:7731 | MARX Biotech Co., Ltd. | 4.26 | -1.08 | -20.21% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026